Ruxolitinib

JUN 30, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Opzelura (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling for an already-approved topical ruxolitinib cream; this record documents a regulatory action, not clinical trial evidence.